Product Program year 2022 Source: CMS Open Payments

Enbrel

Biological Inflammation

NDC 58406-456-04

Open in the dashboard

General payments

$3,366,402

88,040 payments

Research payments

$1,017,722

29 payments

Through program year 2022, $3,366,402 in general payments and $1,017,722 in research payments were reported against Enbrel (Inflammation).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2022 General $1,619,407 43,787
2022 Research $475,345 5
2021 General $1,746,995 44,253
2021 Research $542,376 24

Breakdown

Who paid General payments · program years 2021–2022
  1. Amgen Inc. $3,366,402 88,040 payments
Top recipients General payments · program year 2022
  1. Amar Majjhoo Rheumatology · Saint Clair Shores, MI $51,480 3% · 51 payments
  2. Matthew Farbman Rheumatology · Fort Lauderdale, FL $33,372 2% · 120 payments
  3. Lawrence Leventhal Rheumatology · Huntingdon Valley, PA $31,640 2% · 36 payments
  4. Sanjay Chabra Rheumatology · El Paso, TX $28,353 2% · 64 payments
  5. Aaron Broadwell Rheumatology · Shreveport, LA $26,604 2% · 73 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2022.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2022
  1. Rheumatology Internal Medicine $1,053,138 67% · 2,224 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $107,137 7% · 545 practitioners
  3. Physician Assistant $93,996 6% · 759 practitioners
  4. Dermatology $83,765 5% · 698 practitioners
  5. Internal Medicine $64,904 4% · 310 practitioners

The top 5 of 103 specialties; each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2022
  1. California $229,052 14% · 528 recipients
  2. Florida $193,842 12% · 497 recipients
  3. Texas $154,447 10% · 502 recipients
  4. Pennsylvania $101,669 6% · 215 recipients
  5. Michigan $95,843 6% · 251 recipients

The top 5 of 52 states; each share is of general payments naming this product in 2022 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

362,373

Prescriptions dispensed, refills included

Drug cost

$2,826,294,709

Paid at the pharmacy, in all

Medicare Part D drugs matched to Enbrel, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Enbrel Sureclick Etanercept Similar name 6,066 273,819 $2,147,340,743
Enbrel Etanercept Same name 2,732 62,155 $474,565,056
Enbrel Mini Etanercept Similar name 988 26,399 $204,388,911

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 273 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Jolanta Sobotka-Czarnecki Rheumatology MI 929 $6,887,410 $25
Amanda Matthews Physician Assistant TX 802 $6,426,598 None on record
David Campbell Rheumatology IN 628 $5,094,215 $138
Elvin Garcia Rheumatology TX 628 $4,947,308 None on record
Anne Holly Physician Assistant NY 496 $4,561,988 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 273 with Patron
88,040 general · 29 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record